CRISPR Therapeutics

CRISPR Therapeutics is a biotechnology company focused on developing transformative gene-based therapies for serious diseases. Founded in 2013, the company leverages the revolutionary CRISPR/Cas9 gene-editing technology, co-invented by one of its founders, Dr. Emmanuelle Charpentier, who subsequently won a Nobel Prize for her work. CRISPR Therapeutics is dedicated to translating this groundbreaking technology into potential therapeutics, with a diverse portfolio of programs across various disease areas, including hemoglobinopathies, oncology, diabetes, and cardiovascular disease.

With a patient-forward philosophy, CRISPR Therapeutics prioritizes the development of cures for people suffering from serious diseases. They have achieved the historic milestone of receiving approval in some countries for the first-ever CRISPR-based therapy, CASGEVY™, for certain eligible patients with sickle cell disease or transfusion-dependent beta thalassemia. Committed to pushing the boundaries of science, CRISPR Therapeutics continues to advance its CRISPR-X program, exploring next-generation gene editing and delivery modalities to pave the way for a new era of gene-based medicine.

CRISPR Therapeutics believes in fostering a dynamic workplace that balances remote work flexibility with the benefits of in-person interactions. The company encourages a collaborative work environment, where employees work at least three days on-site, cultivating mentorship opportunities, increasing cross-functional communication, and offering opportunities for employees to connect.

CRISPR Therapeutics offers competitive employee benefits, including skill development courses, manager training, leadership development opportunities, tuition reimbursement, and robust online training libraries. They also provide innovative collaboration spaces, state-of-the-art labs and GMP manufacturing facilities, and support employee well-being.

CRISPR Therapeutics is a biotechnology company pioneering a new era of medicine by developing transformative gene-based therapies for serious diseases. Their mission is to find cures for people suffering from these conditions, innovating for the sake of patients and families and striving to make a positive impact on patients, their communities, and society as a whole.

CRISPR Therapeutics cultivates a culture of innovation, collaboration, and patient-centricity. They believe in empowering their employees to take ownership and actively contribute to the company's mission of developing transformative gene-based medicines. Their commitment to diversity and inclusion fosters a welcoming and inclusive environment where individuals can thrive and contribute their unique perspectives. The company prioritizes employee development, offering opportunities for growth and skill enhancement through various training programs and collaborative work spaces. This dynamic and supportive culture fuels their drive to create innovative therapies that benefit patients and families worldwide.

CRISPR Therapeutics believes that a diverse, equitable and inclusive workplace allows the company to best fulfill its mission. They are committed to increasing diversity throughout the company and fostering an inclusive work environment that supports employees and the communities they serve. They have established a Diversity, Equity, and Inclusion Committee to amplify this focus within the company, and they recruit the best people for the job regardless of gender, race, ethnicity, age, disability, sexual orientation, gender identity, cultural background, or religious belief.